TY - JOUR
T1 - Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine
AU - Sze, Gordon
AU - Brant-Zawadzki, Michael
AU - Haughton, Victor M.
AU - Maravilla, Kenneth R.
AU - McNamara, Michael T.
AU - Kumar, Ashok J.
AU - Aisen, Alex M.
AU - Dreisbach, James N.
AU - Bradley, William G.
AU - Weinreb, Jeffrey C.
AU - Drayer, Burton P.
AU - Tsuruda, Jay S.
AU - Hesselink, John R.
AU - Johnson, Carl E.
AU - Zimmerman, Robert D.
AU - Weingast, Gail R.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1991/12
Y1 - 1991/12
N2 - To evaluate the safety and efficacy of gadodiamide injection, a nonionic gadolinium chelate complex, in magnetic resonance (MR) imaging of the head and spine, a phase II-III trial was conducted in 439 patients with known or suspected lesions in the central nervous system. All patients received gadodiamide injection in a dosage of 0.1 mmol/kg and were monitored; MR images were evaluated for contrast material enhancement. No serious adverse events or clinically important trends in vital signs, laboratory values, or neurologic status were observed. Gadodiamide injection enhanced or facilitated the visualization of lesions in 1266 of 353 patients (75.4%) in whom lesions were shown on unenhanced images, enhanced images, or both; in these 266 patients, the diagnosis was changed in 76 patients (28.6%) and facilitated in 190 patients (71.4%). It is concluded that gadodiamide injection is safe and effective for MR imaging of the head and spine in patients with suspected abnormalities of the central nervous system.
AB - To evaluate the safety and efficacy of gadodiamide injection, a nonionic gadolinium chelate complex, in magnetic resonance (MR) imaging of the head and spine, a phase II-III trial was conducted in 439 patients with known or suspected lesions in the central nervous system. All patients received gadodiamide injection in a dosage of 0.1 mmol/kg and were monitored; MR images were evaluated for contrast material enhancement. No serious adverse events or clinically important trends in vital signs, laboratory values, or neurologic status were observed. Gadodiamide injection enhanced or facilitated the visualization of lesions in 1266 of 353 patients (75.4%) in whom lesions were shown on unenhanced images, enhanced images, or both; in these 266 patients, the diagnosis was changed in 76 patients (28.6%) and facilitated in 190 patients (71.4%). It is concluded that gadodiamide injection is safe and effective for MR imaging of the head and spine in patients with suspected abnormalities of the central nervous system.
KW - Brain neoplasms, MR studies, 10.1214
KW - Brain neoplasms, diagnosis, 10.36
KW - Gadolinium
KW - Magnetic resonance (MR), contrast enhancement
KW - Spine, MR studies, 30.1214
KW - Spine, primary neoplasms, 30.36
UR - http://www.scopus.com/inward/record.url?scp=0026353361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026353361&partnerID=8YFLogxK
U2 - 10.1148/radiology.181.3.1947084
DO - 10.1148/radiology.181.3.1947084
M3 - Article
C2 - 1947084
AN - SCOPUS:0026353361
SN - 0033-8419
VL - 181
SP - 693
EP - 699
JO - Radiology
JF - Radiology
IS - 3
ER -